GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations
GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations
A 510(k) clearance is the U.S. Food and Drug Administration’s permission to market a medical device after the manufacturer shows it is sufficiently similar to one already legally sold. Think of it as getting a green light for a new product because it behaves like an approved model; it allows sales in the U.S. faster than a full approval and reduces regulatory risk, which can materially affect a company’s revenue prospects and valuation.
photon-counting ctmedical
Photon-counting CT is an advanced form of CT scan that detects and counts individual X-ray particles rather than measuring them as a single combined signal, producing clearer images with finer detail and better ability to tell different materials apart. For investors, it matters because the technology can improve diagnostic accuracy, reduce repeat scans and radiation exposure, and open new clinical uses—factors that can drive demand for upgraded scanners, affect hospital purchasing, and influence reimbursement and revenue for medical-imaging suppliers.
deep silicon detectorstechnical
Deep silicon detectors are solid-state sensors made from silicon with a thicker active layer designed to capture radiation or charged particles more efficiently — imagine a thicker sponge catching more raindrops. Investors should care because the deeper design can mean higher sensitivity and better image or sensor performance for medical imaging, security scanners, or scientific instruments, but it can also raise manufacturing complexity, cost and regulatory scrutiny that affect commercial prospects.
intravascular visualizationmedical
Intravascular visualization is the use of tiny cameras or imaging tools placed inside blood vessels to create real-time pictures of the vessel walls, blockages, and medical devices during diagnosis or treatment. Like a plumber’s inspection camera for pipes, it helps doctors see exactly what’s happening, and matters to investors because clear internal images support product effectiveness, regulatory approval, clinical adoption, and reimbursement decisions that affect commercial value.
percutaneous coronary interventionmedical
A minimally invasive heart procedure that opens narrowed or blocked coronary arteries by threading a thin tube from a wrist or groin to the heart and using a balloon and usually a small metal scaffold (stent) to restore blood flow. Investors care because the procedure drives sales and regulatory exposure for device makers, hospitals and suppliers, and influences healthcare costs and insurance payments—think of it like a plumbing repair that requires parts, skilled labor and follow-up maintenance.
cardiac catheterization labmedical
A cardiac catheterization lab is a specialized hospital room where doctors use thin tubes (catheters) and live imaging to diagnose and treat heart problems such as blocked arteries, valve issues, and abnormal rhythms. For investors it matters because the lab concentrates high-cost equipment, disposable devices, procedure volume and reimbursement into a single revenue center—similar to a factory line whose activity and efficiency directly affect hospital income and medical-device sales.
electrocardiodiagram (ecg)medical
An electrocardiodiagram (ECG) is a test that records the heart’s electrical activity as a simple line trace, like a seismograph for heartbeat patterns. It reveals problems such as irregular rhythms or poor blood flow and is a common, objective measure in medical care and clinical trials. Investors watch ECG results because they can affect a drug or device’s safety profile, regulatory approval chances, market acceptance, and potential legal or liability risks.
ce markregulatory
A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.
The company will highlight the newly U.S. FDA 510(k) cleared Photonova Spectra photon-counting CT system, ReadyFix fleet management solution enabled to work with MAC VU360 resting ECG workstations, and a new collaboration to advance interventional cardiology
CHICAGO--(BUSINESS WIRE)--
At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey.
According to the American Heart Association, cardiovascular disease remains the leading cause of death in the United States, with one person dying every 34 seconds and more than 900,000 lives lost each year. As patient volumes rise and nearly half of U.S. adults live with some form of cardiovascular diseasei, clinicians face increasing pressure to detect disease earlier, characterize it more precisely and make confident decisions faster — often with limited time and resources. The solutions GE HealthCare will feature at ACC.26 are designed to help address these demands through ultra‑high‑definition imaging, advanced intravascular visualization, and AI‑supported workflows.
Photon‑counting CT: A new era for cardiac imaging
GE HealthCare will highlight continued advancement in photon‑counting CT with the newly U.S. FDA 510(k) cleared Photonova™ Spectra, an AI‑enabled imaging system, powered by proprietary Deep Silicon detectors. Photon‑counting CT directly measures individual X‑ray photons and their energy, enabling ultra‑high‑definition imaging, improved tissue characterization and enhanced material differentiation. For cardiology, this advancement is designed to support more detailed visualization of coronary anatomy, plaque characterization and dose‑conscious cardiac imaging — with the aim of helping clinicians gain greater diagnostic confidence.
“The cardiology field is entering a new era where imaging quality, data intelligence and workflow efficiency must come together seamlessly,” said Eigil Samset, General Manager, Cardiology Solutions at GE HealthCare. “At ACC.26, we’re showing how innovations like Deep Silicon photon‑counting CT and advanced intravascular imaging can help clinicians see clearly, act confidently and deliver truly personalized heart care across every stage of the patient journey.”
Introducing ReadyFix to help advance operational efficiency and reliability in cardiac care
For the first time at a U.S. cardiology event, GE HealthCare will showcase ReadyFix™ fleet management solutioniienabled to work with MAC VU360™ resting electrocardiodiagram (ECG) workstations. Recently launched in the U.S., ReadyFix works with MAC VU360 to help optimize cardiac care delivery and device uptime through access to real-timeiii data and remote software deployment configuration management and diagnostics. ReadyFix can help health systems proactively maintain and optimize MAC VU360 performance, remotely from a centralized dashboard, to reduce device-related disruptions — supporting care teams in providing consistent, quality care for patients.
GE HealthCare strengthens its vision for the cath lab with new collaboration and innovative technology
At ACC.26, GE HealthCare will highlight how it continues to advance its offerings for the cardiac catheterization lab through intelligent imaging, workflow-focused interventional solutions, and collaborations designed to broaden access to complementary technologies. This includes its recent agreement with Gentuity in the U.S., which will seamlessly connect GE HealthCare customers with Gentuity HF-OCT and Vis-Rx® PRIME Micro-Imaging Catheter.Together, these technologies are designed to support percutaneous coronary intervention planning, and enhanced intraprocedural visualization in complex coronary procedures. This news builds on recent momentum across GE HealthCare’s interventional portfolio, including the recent U.S. FDA 510(k) clearance and CE Mark for Allia Moveo, the latest Allia IGS platform designed to assist clinicians across a wide range of interventional procedures.
“Our focus is on helping clinicians navigate complexity in the cath lab with greater confidence,” said Philip Rackliffe, President and CEO, Advanced Visualization Solutions at GE HealthCare. “Our collaboration with Gentuity is an important example of how we are expanding access to advanced imaging technologies—and empowering clinicians to make critical decisions with greater clarity and precision—while continuing to build on our broader interventional portfolio.”
To learn more about GE HealthCare’s cardiology innovations, please visit this website or engage onsite at ACC.26 at booth #1726. The booth experience includes a guided “Story of the Heart” tour, bringing to life how GE HealthCare supports clinicians across the coronary artery disease care continuum — from triage and diagnosis to procedural guidance.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
i American Heart Association. (2025). Heart disease and stroke statistics—2025 update: A report from the American Heart Association. Circulation, 151, e41–e660. https://doi.org/10.1161/CIR.0000000000001303
ii Use of ReadyFix is limited to ReadyFix-enabled devices. MAC VU360 software version 3.0 is required.
iii Actual time may vary slightly due to hospital network and processing times.
